A systematic review and meta-analysis were performed with the aim to verify whether thienopyridines increased cancer mortality and cancer events. Nine studies have been analyzed including six RCTs and three retrospective cohort studies for a total number of 282,084 participants. All the studies reported on clopidogrel, whereas only two specifically reported on prasugrel. The exposure to clopidogrel showed no association with increased odds of cancer (OR 0.70, 95% CI: 0.66–0.75, n = 1). Furthermore, no significant difference in cancer event rate was pointed out for prasugrel when compared to clopidogrel (OR 1.10, 95% CI: 0.89–1.37, n = 2). Similar results were obtained on the analysis of cancer mortality. On the whole, these data do not support concerns for a class effect of thienopyridines in increasing the cancer event rate and/or mortality (Kotronias et al., 2017).